After a year of expansion and drug approvals, biotechs may face a slowdown – The Boston Globe
0
These are boom times for biotechnology.
Forty-one new drugs were approved for US sale in 2014, the biggest number in 18 years. A record 63 biotech startups went public, breaking the 1999 record of 52 initial public offerings. The value of biopharma merger deals nearly tripled to $223 billion from a year earlier.
Read more – The Boston Globe